Trevena, Inc. (TRVN) EPS Estimated At $-0.26

February 20, 2018 - By Adrian Erickson

 Trevena, Inc. (TRVN) EPS Estimated At $ 0.26

Analysts expect Trevena, Inc. (NASDAQ:TRVN) to report $-0.26 EPS on March, 14.They anticipate $0.41 EPS change or 61.19 % from last quarter’s $-0.67 EPS. After having $-0.27 EPS previously, Trevena, Inc.’s analysts see -3.70 % EPS growth. The stock decreased 0.30% or $0.005 during the last trading session, reaching $1.685. About 341,784 shares traded. Trevena, Inc. (NASDAQ:TRVN) has declined 52.53% since February 20, 2017 and is downtrending. It has underperformed by 69.23% the S&P500.

Trevena, Inc. (NASDAQ:TRVN) Ratings Coverage

Among 14 analysts covering Trevena Inc (NASDAQ:TRVN), 13 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Trevena Inc had 23 analyst reports since August 3, 2015 according to SRatingsIntel. Cowen & Co maintained Trevena, Inc. (NASDAQ:TRVN) on Thursday, August 3 with “Buy” rating. Cowen & Co maintained the shares of TRVN in report on Tuesday, September 1 with “Outperform” rating. The firm has “Buy” rating given on Wednesday, September 2 by JMP Securities. The rating was initiated by Ladenburg Thalmann with “Buy” on Thursday, February 2. The firm has “Equal-Weight” rating given on Monday, October 16 by Barclays Capital. The company was initiated on Monday, August 3 by Brean Capital. As per Wednesday, March 2, the company rating was initiated by WallachBeth Capital. The rating was maintained by Oppenheimer with “Buy” on Friday, July 21. Barclays Capital upgraded it to “Equal-Weight” rating and $18 target in Tuesday, September 1 report. As per Wednesday, March 9, the company rating was maintained by JMP Securities.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The company has market cap of $104.98 million. The Company’s product candidates include oliceridine injection, a µ-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. It currently has negative earnings.

More news for Trevena, Inc. (NASDAQ:TRVN) were recently published by:, which released: “Trevena Promotes Carrie Bourdow to Executive Vice President and Chief …” on February 02, 2018.‘s article titled: “Trevena Announces FDA Acceptance for Review of New Drug Application for OLINVO …” and published on January 02, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.